Loading...
Loading...
SVA| Name | Value |
|---|---|
| Revenues | 307.9M |
| Cost of Revenue | 0.0M |
| Gross Profit | 307.9M |
| Operating Expense | 370.3M |
| Operating I/L | -123.0M |
| Other Income/Expense | 33.6M |
| Interest Income | 55.5M |
| Pretax | -89.4M |
| Income Tax Expense | 138.9M |
| Net Income/Loss | -116.8M |
Sinovac Biotech Ltd. is a biopharmaceutical company based in China, specializing in the research, development, manufacture, and commercialization of vaccines for various infectious diseases. The company's product portfolio includes vaccines for hepatitis A and B, hand, foot, and mouth diseases, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, varicella, mumps, and COVID-19. They generate revenue through the sale of their marketed vaccines, including Healive, Bilive, Anflu, Panflu, Panflu.1, and CoronaVac, as well as through collaboration agreements with other biotech companies for the development of new vaccine candidates.
